CLEC2B: A Potential Drug Target and Biomarker (G9976)

Target Name: CLEC2B

NCBI ID: G9976

CLEC2B

CLEC2B: A Potential Drug Target and Biomarker

CLEC2B (CLC2B_HUMAN), also known as CLC2B, is a protein that is expressed in various tissues of the human body, including the brain, pancreas, and gastrointestinal tract. It is a member of the sprouting angiogenesis factor (SAF) family, which is known for their role in the development and maintenance of blood vessels.

SAF proteins are involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. This is a critical process for the development and maintenance of tissues, including the brain, which requires a constant supply of oxygen and nutrients.

CLEC2B is a 21-kDa protein that is expressed in the brain, pancreas, and gastrointestinal tract. It is characterized by a N-terminus that contains a putative transmembrane domain, a catalytic domain, and a C-terminus that is involved in interactions with other proteins.

The N-terminus of CLEC2B contains a putative transmembrane domain that is responsible for the protein's ability to interact with other membrane-bound proteins. This interaction is likely important for the protein's intracellular localization and its ability to participate in various cellular processes.

The catalytic domain of CLEC2B contains a catalytic active site that is responsible for the protein's catalytic activity. This domain is likely involved in the regulation of cellular processes, including the regulation of angiogenesis.

The C-terminus of CLEC2B is involved in interactions with other proteins. This interaction may be important for the protein's intracellular localization and its ability to participate in various cellular processes.

CLEC2B is a potential drug target because of its involvement in the regulation of angiogenesis. Angiogenesis is a critical process for the development and maintenance of tissues, including the brain, which requires a constant supply of oxygen and nutrients. By targeting the sprouting angiogenesis factor ( SAF) family, including CLEC2B, researchers may be able to develop new treatments for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In addition to its potential as a drug target, CLEC2B is also a potential biomarker. The sprouting angiogenesis factor (SAF) family is known for its role in the development and maintenance of blood vessels, which makes it an attractive target for biomarkers. The expression of CLEC2B in various tissues, including the brain, pancreas, and gastrointestinal tract, suggests that it may be a useful biomarker for the diagnosis and monitoring of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

CLEC2B is also a potential target for small molecules, such as drugs that can modulate its catalytic activity or its ability to interact with other proteins. This suggests that there may be other mechanisms by which clec2b can be targeted, in addition to its role as a drug target.

In conclusion, CLEC2B is a protein that is expressed in various tissues of the human body, including the brain, pancreas, and gastrointestinal tract. It is a member of the sprouting angiogenesis factor (SAF) family, which is known for their role in the development and maintenance of blood vessels. As a potential drug target and biomarker, research into the functions of CLEC2B and its potential therapeutic uses may be valuable for the treatment of various diseases.

Protein Name: C-type Lectin Domain Family 2 Member B

The "CLEC2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets